Urinary Monocyte Chemoattractant Protein and Lupus Nephritis Activity

Sabah Alharazy1*, Norella CT Kong1, Marllyn Mohd2, Shamsul A Shah2, Arbaiyah Báin1 and Abdul Halim Abdul Gafor2

1Nephrology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
2Department of Microbiology & Immunology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

Abstract

Objective: Monocyte chemoattractant protein-1 (MCP-1) is reported to be associated with lupus nephritis (LN) activity. We therefore investigated urinary MCP-1 (uMCP-1) in patients with biopsy proven LN.

Methods: This was a cross-sectional observational study in which uMCP-1 levels and the standard parameters of LN activity were measured in these patients.

Results: One hundred patients were recruited: 47 with active and 53 inactive LN. uMCP-1 levels were increased in those with active LN [9.317.5 pg/mg creatinine (5.48,3-40.170)] compared to those with inactive LN [3.682 pg/mg creatinine (0-23,866)] (p<0.001). uMCP-1 correlated with proteinuria (r=0.39, p=0.001), serum albumin (r=-0.35, p=0.001) and SLEDAI-2K (renal) (r=0.39, p=0.001). Area under receiver operator characteristic (AUROC) curve for uMCP-1 was 0.82 (p=0.001) compared with 0.50 (p=0.95), 0.37 (p=0.50), 0.43 (p=0.26) for anti-ds-DNA Ab, C3 and C4 respectively. AUROC for proteinuria was 0.94 (p<0.001) and for SLEDAI-2K (renal) was 0.96 (p<0.001). Only proteinuria and SLEDAI-2K (renal) were independent predictors of LN activity.

Conclusions: uMCP-1 may provide further adjunctive evidence if the clinical diagnosis of LN activity remains uncertain and facilitate improved grading of renal disease activity in this complex disease thus leading to improved treatment and outcome. Serial measurements of uMCP-1 are indicated.

Keywords: Lupus nephritis (LN); Urinary monocyte chemoattractant protein-1 (uMCP-1); Biomarker; Renal flare

Introduction

Lupus nephritis (LN) is a frequent and serious complication of Systemic Lupus Erythematosus (SLE) and is associated with considerable morbidity and mortality [1,2]. The disease course is characterized by unpredictable flares.

The conventional laboratory markers used in clinical practice such as serum complement levels and double-stranded DNA antibodies are unreliable indicators of LN as they lack both sensitivity and specificity for prediction of active or relapsing LN. Moreover, serum creatinine is also unsatisfactory as a marker as significant renal damage can occur before it rises [3]. Other laboratory tests such as proteinuria and urinary sediments are also non-specific markers [4].

Renal biopsy remains the gold standard for the evaluation of LN disease activity. However, it is an invasive procedure and serial renal biopsies are not appropriate in clinical practice. Hence, it is very important to identify noninvasive new biomarkers that are able to predict renal flares and/or reflect its activity. These biomarkers could then be followed serially and would enable timely institution of appropriate treatment before the development of significant inflammatory injury in the kidney. Early treatment may also lead to early and more complete remission and less chronic kidney damage [5,6] as well as decrease the patient’s total exposure to immunosuppressive medications and their toxicities. Evidence in human and animal studies have demonstrated the pathogenic role of MCP-1 in renal injury in LN [7,8].

Several studies in LN patients have shown that uMCP-1 to be associated with LN [9] and its severity [10] and flares [11].

We therefore investigated the usefulness of uMCP-1 levels as a marker of LN activity in SLE patients with biopsy proven LN.

Methods

This was a cross-sectional study which recruited consecutive SLE patients with biopsy proven LN [12] attending the Nephrology /SLE Clinic at our centre. This study was carried out between 9 December 2011 and 4 August 2012. We excluded those patients with end stage renal disease (ESRD) or had undergone renal transplantation, pregnant patients, patients in whom a renal biopsy could not be performed and those unable to give consent eg. due to cerebral lupus. The patients were divided into two groups based on the presence or absence of LN activity. Patients with relapse/ flare of LN were included in the active group.

Ethical aspects

This study was approved by the Medical Research and Ethics Committee of the Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Informed consent was taken from all participating subjects.

SLE disease activity index assessment

Lupus disease activity was assessed by the various components of the SLE Disease Activity Index (SLEDAI-2K) [13] comprising global (score range 0-150), extrarenal (score range 0-63) and renal (score range 0-16). The renal score was based on the presence of any of the following abnormal parameters in the urinalysis in the absence of stones, urinary tract infection or other causes: haematuria (≥5 red...
blood cells/high power field (HPF), leukocyturia (≥5 leukocytes/HPF) and urinary casts (granular or red blood cell casts) [14].

Definition of LN activity
A. Active LN was defined by the presence of one or more of the following criteria:
   I. Proteinuria with or without any of the following features [15].
      a) Presence of haematuria and/or red cell casts
      b) Increase in serum creatinine or decline in eGFR
   Proteinuria was measured as spot morning urine protein creatinine index (uPCI) and was positive if the value was >1000 mg/mmol (NR ≤ 200).
   II. Renal SLEDAI score ≥ 4 [13].
B. Relapse/flare of LN was defined as recurrence of renal disease activity after a period of remission ≥ 3 months for the purpose of this study [15].
C. Remission was defined as absence or reduction of renal disease activity and no change in immunosuppressive therapy for at least 3 months [15].
D. Inactive LN was defined by the presence of one or more of the following criteria:
   I. Proteinuria (uPCI) <500 mg/mmol with/without any of the following features:
      a) Serum albumin ≥ 35 g/L
      b) Inactive urine sediments (<5 red cells/HPF and no red cell casts and no leucocyturia (<5 white cells/HPF)
      c) Stable serum creatinine (unless due to other etiology eg. renin-angiotension system (RAS) blockade) [15]
   II. Renal SLEDAI score 0 or<4

Clinical and laboratory measurements
Each patient was evaluated using clinical and laboratory parameters. The latter included full blood count, renal function test, eGFR using the Modification of Diet in Renal Disease (MDRD) formula, urine analysis by dipstick, urine microscopy, urine protein creatinine index (uPCI), erythrocyte sedimentation rate (ESR), serum complement levels C3 and C4 and anti–ds DNA antibody titres. Fresh urine samples obtained for uMCP-1 testing were immediately centrifuged to remove sediments and then frozen in aliquots at -80°C for uMCP-1 testing as a batch.

Urine MCP-1 measurement
The levels of uMCP-1 were measured by specific enzyme-linked immunoassay (ELISA) kits (Minneapolis, Minn, USA, R&D Systems). Briefly, urine samples were diluted according to the manufacturer’s directions. Standard or test samples were added to each well and left to incubate for 2 hours at room temperature. Conjugate was added after washing the plates to remove any unbound substances then was incubated for an hour. Substrate solution was next added after washing the plates. Stop solution was added after incubation for 20 min at room temperature. Finaly, the absorbance was read at 450 nm with the correction wavelength set at 540 nm. All samples were assayed in duplicate. uMCP-1 levels were expressed as concentrations normalized for urine creatinine and presented as picograms per milligram creatinine (pg/mg).

Sample size calculation
The sample size was calculated using the formula advocated by Jones et al. [16]:

\[
TP + FN = Z^2 \times \frac{(SN (1-SN))}{W^2}
\]
TP=True positive
FN=False negative
\[z^2= A number relating to degree of confidence, for 95% confidence the value was 1.96.\]
SN=Expected level of sensitivity of urinary MCP-1 for early detection of LN flare in this study.
W=Confidence interval for sensitivity.
For purposes of calculation W was set at 0.1.
The power of the study was set at 80%.
Based on the criteria above, the required number of patients for the study was 93 patients.
However, 100 patients completed the study.

\[
= 1.96^2 \times \frac{0.90 (1 - 0.90)}{0.1^2}
= 3.842 \times 0.09
= 0.37
\]
N(SN) = \[\frac{TP + FN}{P}\]
P=Expected prevalence of LN flare in this study (37%)
LN flare ranging in different studies from 27% to 66% [17].

Statistical analysis
Kolmogorov-Smirnov test was used to determine the normal distribution for each variable. Normally distributed variables were presented as mean ± standard deviation (SD) while non-normally distributed data were presented as median ± interquartile range (IQR). The Pearson’s chi-square test (χ2) test was used to compare categorical variables; the two-sided independent-sample t test was used for comparison of means whereas the non-parametric Mann-Whitney U test and Kruskal-Wallis test were used for non-normally distributed variables. Correlation between uMCP-1 levels with relevant laboratory parameters were assessed using Spearman’s correlation coefficients. Receiver operating characteristic (ROC) curves were generated and the area under the curve (AUC) was used to measure the discriminatory capacity of uMCP-1 levels for identification of LN activity. The AUC for uMCP-1 was compared with those of the standard markers of LN activity. The best cut-off value for uMCP-1 was calculated on the basis of maximization of the Youden index (sensitivity+specificity − 1)
shown in Table 2. Azathioprine (p=0.04). Detailed comparisons between both groups are presented in Table 1. There were no differences in their demographic, LN duration, renal biopsy classes and pathologic scores as well as CKD stages.

### Results

#### Demographic and clinical characteristics of the study patients

One hundred patients with SLE and biopsy proven LN were recruited. Their baseline clinical characteristics are listed in Table 1. There were 47 patients with active LN and 53 with inactive LN. There were no differences in the use of corticosteroids, hydroxychloroquine, renin angiotension system (RAS) blockers (ACE-inhibitors and/or ARBs and/or spironolactone). However, there was a difference with regards the use of immunosuppressive medications between the two groups viz. Cyclophosphamide, Mychophenolic acid, Azathioprine, Hydroxychloroquine, and SLEDAI-2K (renal). There were no differences between the groups with regards the use of corticosteroids, hydroxychloroquine, renin angiotension system blockers (ACE-inhibitors and/or ARBs and/or spironolactone). However, there was a difference with regards the use of immunosuppressive medications between the two groups viz. cyclophosphamide (p=0.002), cyclosporine or tacrolimus (p=0.03) and azathioprine (p=0.04). Detailed comparisons between both groups are shown in Table 2.

### Comparison between patient groups

Patients with active LN had lower serum albumin, higher proteinuria, and uMCP-1 levels, higher scores for SLEDAI-2K (global) and SLEDAI-2K (renal). There were no differences between the groups with regards the use of corticosteroids, hydroxychloroquine, renin angiotension system (RAS) blockers (ACE-inhibitors and/or ARBs and/or spironolactone). However, there was a difference with regards the use of immunosuppressive medications between the two groups viz. cyclophosphamide (p=0.002), cyclosporine or tacrolimus (p=0.03) and azathioprine (p=0.04). Detailed comparisons between both groups are shown in Table 2.

### Values in median (interquartile range) or mean (standard deviation). [p values were calculated by Mann-Whitney U test or Independent sample T test]; LN: Lupus Nephritis; WBC: White Blood Cell count; eGFR: Estimated Glomerular Filtration Rate; uPCI: Urine Protein Creatinine Index; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index-2K; anti-dsDNA: Anti Double Stranded DNA; C3: Complement 3; C4: Complement 4.

### Table 2: Comparison between patients with and without active LN.

### Urinary MCP-1 levels and correlation with clinical and laboratory parameters

SLE patients with active LN had significantly higher uMCP-1 [9,317.5 pg/ mg creatinine, IQR (548.3-40,170)] than those with inactive LN [3,682 pg/ mg creatinine, IQR (0-23,866)] (p<0.001) as illustrated in Figure 1.

There were no associations between uMCP-1 levels and use of steroids, renin angiotension system blockers (ACEI / ARB / Spironolactone) or immunosuppressive medications other than for intravenous cyclophosphamide. uMCP-1 levels were higher in patients treated with cyclophosphamide [11,677.2 pg/mg creatinine, IQR (548.3-40,170)] than those with uMCP-1 1 [9,317.5 pg/mg creatinine, IQR (548.3-40,170)] and uMCP-1 10 (18.9) than those with uMCP-1 12 (25.5) than those with uMCP-1 20 (41.5) than those with uMCP-1 22 (41.5) than those with uMCP-1 29 (61.7) than those with uMCP-1 Values are in median (interquartile range) or mean (standard deviation). [p values were calculated by Mann-Whitney U test or Independent sample T test]; LN: Lupus Nephritis; WBC: White Blood Cell count; eGFR: Estimated Glomerular Filtration Rate; uPCI: Urine Protein Creatinine Index; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index-2K; anti-dsDNA: Anti Double Stranded DNA; C3: Complement 3; C4: Complement 4.

### Table 3: Comparison between patients with and without active LN.

### Diagnostic performance of uMCP-1 in LN

To assess the potential diagnostic values of uMCP-1 in comparison
to the standard markers for the identification of SLE patients with active LN, a ROC curve was constructed. At a cut off of 4,247 pg/mg creatinine with a maximum Youden index of 0.48, the sensitivity of uMCP-1 for early diagnosis of active LN was 0.87 with a specificity of 0.61. The area under the curve (AUC) was 0.82 (95% CI: 0.73-0.91: p=0.001). In comparison, the AUC for anti dsDNA Ab titres was 0.50 (95% CI: 0.37-0.63: p=0.95) and those for serum C3 and serum C4 were 0.37 (95% CI: 0.25-0.50: p=0.50) and 0.43 (95% CI: 0.30-0.56: p=0.26) respectively (Figure 3).

The AUC for proteinuria (uPcI) was 0.94, (95% CI: 0.89-0.98: p=0.95: p<0.001) and that for SLEDAI-2K renal score were 0.96 (95% CI: 0.71-0.90: p<0.001) (Figure 4A). The AUCs for haematuria,
leucocyturia were 0.72 (95% CI: 0.60-0.84; p=0.001) and 0.65 (95% CI: 0.52-0.77; p=0.23) respectively.

The AUC for serum albumin was 0.25 (95% CI: 0.13-0.35; p=0.001), that for serum creatinine was 0.58 (95% CI: 0.44-0.71; p=0.95; p=0.21) and that for eGFR was 0.41 (95% CI: 0.28-0.55; p=0.21) (Figure 4B).

The AUC for uMCP-1 was higher than that for anti dsDNA Ab titres, C3, C4, serum albumin, serum creatinine, eGFR, haematuria and leucocyturia for detection of LN activity. Whereas it was lower than these for proteinuria (uPCI) and SLEDAI-2K renal score.

Thus, uMCP-1 was superior to the serological and usual biochemical markers but was not as good as proteinuria (uPCI) and SLEDAI-2K renal score for detection of LN activity.

| Spearman’s rho variable | $r$ | $p$ value |
|-------------------------|-----|-----------|
| Haemoglobin             | -0.11 | 0.25     |
| White blood cells       | -0.06 | 0.56     |
| Platelets               | 0.05  | 0.57     |
| Serum albumin           | -0.35 | 0.001    |
| Serum creatinine        | 0.09  | 0.38     |
| eGFR                    | -0.10 | 0.30     |
| C3 (mg/dl)              | -0.09 | 0.34     |
| C4 (mg/dl)              | 0.02  | 0.80     |
| Anti dsDNA Ab titres    | -0.04 | 0.64     |
| Urine protein creatinine index (uPCI) | 0.39 | 0.001 |
| Leucocyturia            | 0.26  | 0.008    |
| Haematuria              | 0.13  | 0.18     |
| SLEDAI-2K global score  | 0.28  | 0.006    |
| SLEDAI-2K renal score   | 0.38  | 0.001    |
| SLEDAI-2K-extra renal score | -0.08 | 0.42     |

$r$: Spearman’s rho correlation coefficient; eGFR: Estimated Glomerular Filtration Rate; C3: Complement 3; C4: Complement 4; anti dsDNA: Anti Double Stranded DNA; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index-2K.

Table 3: Association between uMCP-1 and laboratory parameters.
Independent predictors of LN activity

Binary logistic regression was performed to assess the independent predictors for LN activity. uMCP-1 and all variables clinically relevant to LN activity with a p value ≤ 0.05 (Table 2) were entered in the regression model. These included serum albumin, proteinuria (uPCI) and SLEDAI-2K.

Only proteinuria (odds ratio (OR)=9.76, 95% CI, 0.32-99.67, p=0.03) and SLEDAI-2K renal score (OR=3.62, 95% CI, 1.82-7.22, p=0.001) were independent predictors of LN activity (Table 4).

Discussion

Renal involvement in SLE contributes significantly to patient morbidity and mortality [19]. Hence, it is essential to find a noninvasive biomarker that could be used for the monitoring of LN disease activity as well as early diagnosis of flares [20]. In this cross-sectional study of 100 patients with LN, we evaluated the role of uMCP-1 levels as a noninvasive biomarker for LN activity and investigated its correlations with current standard laboratory markers and disease activity indices.

MCP-1 is a chemotactic cytokine that is expressed by various renal cells in response to stimulation with proinflammatory cytokines and immune complexes (IC) [21]. This in turn leads to mononuclear cell infiltration of the kidneys in LN. These renal cells include the glomerular endothelial, mesangial as well as tubular epithelial cells.

Many studies have demonstrated the role of MCP-1 in the pathogenesis and progression of glomerular and tubulointerstitial injury in both murine and human LN [22-24]. Tesch et al. [25] reported that MRL/lpr mice with MCP-1-deficiency exhibit prolonged survival when compared to MCP-1+/+MRL/lpr mice as they lack renal macrophages such that T cell infiltration does not occur in response to renal injury and are thus protected from renal damage. Furthermore, glomerular and interstitial inflammation as well as kidney damage were all markedly reduced in these mice after the injection of pharmacologic blockade of MCP-1 [26].

In patients with LN, the presence of MCP-1 in the urine indicates its intrarenal expression [10,27,28] and this correlated significantly with the degree of leukocyte infiltration in the kidneys [28]. In follow up studies, uMCP-1 levels were also found to be increased in patients.
with active LN and reduced with treatment-induced disease remission [10,29-32].

It appears that uMCP-1 may be a useful clinical marker for predicting and monitoring LN activity. Singh et al. [33] in a longitudinal study (20 patients) reported that uMCP-1 can distinguish between those patients with active LN from those with inactive renal disease or stable SLE.

Our study (n=100) also demonstrated that uMCP-1 levels were significantly elevated in patients with active LN compared to those with inactive renal disease. uMCP-1 levels also correlated directly with proteinuria and inversely with serum albumin. These findings corroborate with those reported by Tucci et al. [27], Chan et al. [34] and Alzawawy et al. [35]. The two latter authors also observed the same significant correlation between uMCP-1 levels and proteinuria. Whereas Noris et al. [28] did not find this relationship.

In a recent report of LN patients (n=83) with juvenile onset of SLE, Watson et al. [36] also found that uMCP-1 levels were higher in those patients with active renal disease. Like us, they found no association between uMCP-1 levels and serum creatinine or eGFR. On the other hand, other studies [27,34,37,38] have reported that uMCP-1 levels were associated with serum creatinine. These findings were also demonstrated by Rovin et al. [11] in a longitudinal study of 89 patients with SLE.

Our findings of a high correlation between uMCP-1 with global SLEDAI-2K and renal SLEDAI-2K scores had previously been reported by many authors. These include Rovin et al. [11], Chan et al. [34], El-shehaby et al. [37] and Rosa et al. [38].

Due to the lag time between the urine samples obtained for uMCP-1 assays and renal biopsies, we were not able to correlate this biomarker with LN classes as the histological features of LN would have changed with time and treatment.

There were no associations between the third and fourth components of serum complement (C3, C4) and anti dsDNA antibody titres with uMCP-1 levels. These findings concur with those reported by Watson et al. [36]. On the other hand, El-shehaby et al. [37] noted that uMCP-1 levels were associated with serum complements C3 and C4. Whereas Chan et al. [34] demonstrated a significant correlation between urinary mRNA expression of MCP-1 with SLE disease activity indices and anti dsDNA antibody titres in patients with active LN during treatment with immunosuppressive medications. Similary, Kiani et al. [39] in a longitudinal study of SLE patients (n=87) found a significant correlation between uMCP-1 levels with anti dsDNA positivity.

Contrary to all the above, Tucci et al. [27] found the uMCP-1 levels to be decreased in his cohort of LN patients during treatment with IV Cyclophosphamide. In our study, uMCP-1 levels were higher in those patients who received treatment with IV cyclophosphamide than those who did not. This can be explained by the fact that those patients who were treated by IV cyclophosphamide (n=8) had severe SLE/LN and were in the early stages of their treatment. Here, the high uMCP-1 levels most likely reflected the activity and severity of their LN. Their high uMCP-1 levels also correlated with persistently high proteinuria. Both parameters may indicate ongoing kidney inflammation which in turn may lead to adverse renal outcome. Although there were significant associations between the use of calcineurin inhibitor and azathioprine with LN disease activity, uMCP-1 levels did not differ with the use of these immunosuppressive medications. On the other hand, uMCP-1 levels were not related to the use of corticosteroids or remin angiotension system (RAS) blockers. Rovin et al. [11] also found that uMCP-1 levels were not related to the cumulative dose of steroids or immunosuppressive medications neither received within 30 days preceding a renal flare nor were the uMCP-1 levels related to the use of RAS blockers. Whereas Wada et al. [10] reported that uMCP-1 levels decreased after commencing high dose corticosteroid therapy in LN patients particularly in those with LN Class IVb.

The role of anti dsDNA Ab titres and serum complement levels in reflecting LN disease activity or predicting LN outcome remain controversial [40]. In our LN cohort, the anti dsDNA Ab titres and serum complement levels were not associated with LN activity. These were tested at 2-monthly intervals which may be too short an interval for reflection of changes in renal disease activity. However, these findings are consistent with those reported by others [41,42]. Moroni et al. demonstrated that only anti-C1q antibodies associated significantly with LN activity whereas anti dsDNA Ab, C3 and C4 did not [41]. Esdaile et al. evaluated anti dsDNA Ab, C3, C4, and C1q as predictors of renal, nonrenal flares and all flares combined and did not find any of these to be useful [42]. However, other studies have reported that raised anti dsDNA Ab levels was associated with active renal disease [43,44] and that decline in C3 or C4 levels coincided with an increase in LN activity [45].

In a recent report, Abujam et al. demonstrated uMCP-1 to be superior to serum C4 and urinary CXCL10/IP-10 in this regard but of equivalent efficacy to anti dsDNA Ab titres and serum C3 in differentiating active LN from non renal SLE [46]. In this current study, the ROC curve for uMCP-1 showed that it had a good diagnostic profile for early detection of LN activity and outperformed anti ds DNA Ab titres, serum C3, C4, and usual biochemical markers. However, it was not as good as proteinuria (uPCI) and SLEDAI-2K renal score for detection of LN activity.

Multiple logistic regression analysis showed that only proteinuria and SLEDAI-2K renal score were independent predictors of LN activity. This is not surprising since this renal score is an amalgamate of urinary abnormalities in active LN. Moreover, proteinuria and increased SLEDAI-2K renal score were used as main criteria in our definition of LN activity.

Although uMCP-1 was not an independent predictor for clinically or overtly active LN, it is well known that patients with clinically active LN have a spectrum of renal involvement on renal biopsy which may range from histopathologically severe disease to varying levels of downgrading activity in response to treatment. Similarly, patients with clinically inactive LN also have varying grades of renal histopathologic findings ranging from total quiescence to low grade 'grumbling' disease to early 'subclinical' relapse. This dilemma further lends support to the inclusion of uMCP-1 to the current clinical markers as a fine-tuning tool for following LN activity. Thus, uMCP-1 may be a useful adjunctive diagnostic tool to further discriminate between clinically active and inactive LN in this complex disease.

Early treatment of LN may lead to earlier and more complete remission (CR), decreases progression to chronic kidney disease (CKD) and end stage kidney disease (ESKD), decreases total exposure to immunosuppressive medications and their toxicities and results in overall improved patient outcome.

In conclusion, uMCP-1 may provide further adjunctive evidence if the clinical diagnosis of LN activity remains uncertain and facilitate improved grading of nephritis activity in this complex disease thus leading to early treatment and better outcome. Serial measurements of...
uMCP-1 may also allow us to follow the course of LN during treatment after the initial renal biopsy without resort to repeated biopsies in the majority of such patients. We are following this cohort of 100 LN patients longitudinally and hope to report these results in the near future.

Acknowledgements

This paper was presented as a poster [SU183] at the International Society of Nephrology (ISN), World Congress of Nephrology (WCN) 2013 Hong Kong, May 31-June 2013. We thank the Dean and Medical Director of the UMMC for his kind permission to publish these data. We are grateful to Rahimah Ismail and Rafidah Marran for helping with preparation of urine samples for the MCP-1 assays. This study was supported by a grant from the Faculty of Medicine, UKM [FF-446-2011] and another from the MAA Medicare Kidney Charity Fund.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, et al. (2000) Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 35: 904-914.
2. Reyes-Thomas J, Blanco I, Puttermann C (2011) Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 40: 136-150.
3. Hewitt SM, Dear J, Star RA (2004) Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 15: 1677-1689.
4. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, et al. (2006) Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 54: 2577-2584.
5. Fiehn C, Hajar Y, Mueller K, Waldtherr R, Ho AD, et al. (2003) Improved clinical outcome of lupus nephritis during the past decade: Importance of early diagnosis and treatment. Ann Rheum Dis 62: 435-439.
6. Housiaux FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, et al. (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Arthritis Rheum 50: 3934-3940.
7. Rovin BH, Phan LT (1996) Chemotactic factors and renal inflammation. Am J Kidney Dis 31: 1065-1084.
8. Kelley VR, Rovin BH (2003) Chemokines: therapeutic targets for autoimmune and inflammatory renal disease. Springer Semin Immunopathol 24: 411-421.
9. Kuroiwa T, Lee EG (1998) Cellular interactions in the pathogenesis of lupus nephritis: the role of T cells and macrophages in the amplification of the inflammatory process in the kidney. Lupus 7: 597-603.
10. Wada T, Yokoyama H, Su SB, Mukaida N, Iwamo M, et al. (1996) Monitoring urinary levels of monocyte chemoattractant and activating factor reflects disease activity of lupus nephritis. Kidney Int 49: 761-767.
11. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, et al. (2005) Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16: 467-473.
12. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
13. Gladman DD, Ibáñez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29: 289-291.
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35: 630-640.
15. Kong N et al (2011) Pulse Cyclophosphamide versus added dual filtration plasmapheresis (DFPP) therapy for severe lupus nephritis. UKRM research clinical trial code (FF – 324 – 2011) (Unpublished).
16. Jones S, Carley S, Harrison H (2003) An introduction to power and sample size estimation. Emerg Med J 20: 453-458.
17. Sidiropoulos PI, Kritikos HD, Boumpas DT (2005) Lupus nephritis flares. Lupus 14: 49-52.
18. Youden WJ (1950) Index for rating diagnostic tests. Cancer 3: 32-35.
19. Cameron JS (1999) Lupus nephritis. J Am Soc Nephrol 10: 413-424.
20. Schwartz N, Su L, Burky LC, Mackay M, Aranow C, et al. (2006) Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 27: 242-250.
21. Segerer S, Nelson PJ, Schröndorf D (2000) Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11: 152-176.
22. Stahl RA, Thaiss F, Disser M, Helmchen U, Hora K, et al. (1993) Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int 44: 1036-1047.
23. Rovin BH, Doe N, Tan LC (1996) Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 27: 640-646.
24. Saitoh A, Suzuki Y, Takeda M, Kubota K, Itoh K, et al. (1998) Urinary levels of monocyte chemoattractant protein (MCP-1) and disease activity in patients with IgA nephropathy. J Clin Lab Anal 12: 1-5.
25. Tesch GH, Maierl S, Schwarting A, Rollins BJ, Kelley VR (1999) Monocyte chemoattractant protein-1 independent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 190: 1813-1824.
26. Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, et al. (2003) Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 48: 2555-2566.
27. Tucci M, Barnes EV, Sobel ES, Crocker BP, Segal MS, et al. (2004) Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 50: 1842-1849.
28. Noris M, Bernasconi S, Casiraghi F, Sozzani S, Gott E, et al. (1995) Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 73: 804-809.
29. Wada T, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, et al. (1994) Detection of urinary interleukin-8 in glomerular diseases. Kidney Int 46: 455-460.
30. Wada T, Furuchi K, Sakai N, Iwata Y, Yoshimoto K, et al. (2000) Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58: 1492-1499.
31. Tesar V, Masek Z, Rychlik I, Merta M, Bartůnková J, et al. (1998) Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 13: 1662-1667.
32. Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY (2000) Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85: 207-214.
33. Singh RG, Usha, Rathore SS, Behura SK, Singh NK (2012) Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare. Lupus 21: 1214-1218.
34. Chan RW, Lai FM, Li EK, Tam LS, Wong TY, et al. (2004) Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 50: 2882-2890.
35. Alzawawy A, Zohary M, Abdordiny M, Eldalie M (2009) Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis. Int J Rheum Dis 12: 311-318.
36. Watson L, Midgley A, Pilkington C, Tullus K, Marks S, et al. (2012) Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus 21: 496-501.
37. El-Shemyy A, Darweesh H, El-Khatib M, Montaz M, Marzouk S, et al. (2011) Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 31: 848-856.
38. Rosa RF, Takii K, Araujo NC, Szajubok JC, et al. (2012) Monocyte chemoattractant-1 as a urinary biomarker for the diagnosis of activity of lupus nephritis in Brazilian patients. J Rheumatol 39: 1948-1954.
39. Kiani AN, Johnson K, Chen C, Diehl E, Hu H, et al. (2009) Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J Rheumatol 36: 2224-2230.
40. Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 50: 2048-2065.
41. Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, et al. (2001) Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37: 490-498.
42. Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, et al. (1996) Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 23: 1891-1896.
43. Spronk PE, Bootsma H, Kallenberg CG (1998) Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment? Clin Rev Allergy Immunol 16: 211-218.
44. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, et al. (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345: 1595-1599.
45. Ho A, Barr SG, Magder LS (2001) A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 44: 2350-2367.
46. Abujam B, Cheekatla S, Aggarwal A (2013) Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis. Lupus 22: 614-623.